Abilify: Restoring Balance in Mental Health Treatment
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.14 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $81.20 $70.18 (14%) | 🛒 Add to cart |
| 180 | $0.66 | $162.41 $118.30 (27%) | 🛒 Add to cart |
| 270 | $0.62 | $243.61 $166.42 (32%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $324.81 $214.54 (34%) | 🛒 Add to cart |
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.54 | $46.12 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $92.23 $65.16 (29%) | 🛒 Add to cart |
| 90 | $0.94 | $138.35 $84.21 (39%) | 🛒 Add to cart |
| 120 | $0.85 | $184.46 $102.26 (45%) | 🛒 Add to cart |
| 180 | $0.79 | $276.69 $141.35 (49%) | 🛒 Add to cart |
| 270 | $0.74 | $415.04 $198.50 (52%) | 🛒 Add to cart |
| 360 | $0.70
Best per pill | $553.38 $253.63 (54%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.47 | $74.19 (0%) | 🛒 Add to cart |
| 60 | $1.75 | $148.37 $105.26 (29%) | 🛒 Add to cart |
| 90 | $1.51 | $222.56 $136.34 (39%) | 🛒 Add to cart |
| 120 | $1.39 | $296.74 $166.42 (44%) | 🛒 Add to cart |
| 180 | $1.27 | $445.11 $228.57 (49%) | 🛒 Add to cart |
| 270 | $1.19 | $667.67 $321.81 (52%) | 🛒 Add to cart |
| 360 | $1.15
Best per pill | $890.23 $414.04 (53%) | 🛒 Add to cart |
Synonyms | |||
Abilify (aripiprazole) is an atypical antipsychotic medication representing a significant advancement in neuropsychopharmacology. It functions as a dopamine system stabilizer, offering a unique mechanism of action that modulates dopamine and serotonin activity rather than simply blocking receptors. This sophisticated pharmacological profile makes it a versatile agent in the treatment of various psychiatric conditions, from schizophrenia and bipolar disorder to adjunctive treatment of major depressive disorder. Its partial agonist activity at D2 and 5-HT1A receptors, combined with antagonist activity at 5-HT2A receptors, provides a balanced approach to managing complex neurochemical imbalances while potentially minimizing certain adverse effects associated with earlier generation antipsychotics.
Features
- Contains aripiprazole as the active pharmaceutical ingredient
- Available in multiple formulations: tablets, orally disintegrating tablets, oral solution, and injectable forms
- Features a unique pharmacodynamic profile as a dopamine partial agonist
- Offers once-daily dosing convenience for most formulations
- Provides long-acting injectable option (Abilify Maintena) for improved adherence
- Demonstrated efficacy across multiple psychiatric indications
- Extensive clinical trial database supporting its use
- Multiple strength options for precise dosing titration
Benefits
- Effectively reduces positive and negative symptoms of schizophrenia
- Helps stabilize mood episodes in bipolar disorder
- Provides adjunctive benefit when combined with antidepressants for treatment-resistant depression
- Demonstrates favorable metabolic profile compared to some other antipsychotics
- Offers flexible dosing and administration options to meet individual patient needs
- May cause less sedation and weight gain than some alternative treatments
Common use
Abilify is commonly prescribed for the treatment of schizophrenia in adults and adolescents aged 13-17 years. It is also FDA-approved for the acute treatment of manic and mixed episodes associated with bipolar I disorder in adults and pediatric patients 10-17 years old, as well as for maintenance treatment in adults. Additionally, it is indicated for use as an adjunctive treatment to antidepressants for major depressive disorder in adults. Off-label uses may include irritability associated with autistic disorder in pediatric patients (though other formulations are specifically approved for this indication), treatment of Tourette’s syndrome, and as augmentation therapy in treatment-resistant obsessive-compulsive disorder.
Dosage and direction
Dosage varies significantly based on indication, patient age, and formulation. For schizophrenia in adults, the recommended starting dose is 10-15 mg once daily, with a target dose of 15 mg daily and a maximum of 30 mg daily. For bipolar mania, adults typically start with 15 mg once daily, which may be increased to 30 mg daily if needed. As adjunctive treatment for depression, the starting dose is 2-5 mg daily, with increases of up to 5 mg at weekly intervals to a maximum of 15 mg daily. Pediatric dosing requires careful weight-based calculation and gradual titration. Long-acting injectable Abilify Maintena is administered monthly after initial oral stabilization. All dosing should be individualized based on clinical response and tolerability, under close medical supervision.
Precautions
Patients should be monitored for the emergence of suicidal thoughts and behaviors, particularly during initial treatment and dose adjustments. Regular assessment of weight, blood glucose, and lipid parameters is recommended due to potential metabolic effects. Caution is advised in patients with cardiovascular disease, cerebrovascular disease, or conditions that predispose to hypotension. Abilify may impair judgment, thinking, or motor skills; patients should be cautioned about operating hazardous machinery or driving until they know how the medication affects them. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death and should be carefully monitored. Discontinuation should be gradual to avoid withdrawal symptoms or rapid recurrence of underlying condition.
Contraindications
Abilify is contraindicated in patients with known hypersensitivity to aripiprazole or any components of the formulation. The injectable form is contraindicated in patients with known hypersensitivity to polysorbate 80. Use is contraindicated in combination with strong CYP3A4 inhibitors like ketoconazole or strong CYP2D6 inhibitors like quinidine, or with strong CYP3A4 inducers like carbamazepine, unless dose adjustments are carefully implemented. It should not be used in patients with severe hepatic impairment without careful risk-benefit assessment.
Possible side effect
Common side effects may include akathisia (inner restlessness), headache, anxiety, insomnia, nausea, vomiting, constipation, dizziness, and blurred vision. Extrapyramidal symptoms may occur, including dystonia, Parkinsonism, and tardive dyskinesia. Weight gain, though generally less than with some other antipsychotics, may occur. Metabolic changes including increased blood glucose and lipids have been reported. Rare but serious side effects include neuroleptic malignant syndrome, seizures, orthostatic hypotension, dysphagia, and cognitive impairment. Some patients may experience pathological gambling or other compulsive behaviors.
Drug interaction
Abilify is primarily metabolized by CYP3A4 and CYP2D6 enzymes, creating potential for numerous interactions. Strong CYP3A4 inhibitors (ketoconazole, itraconazole) and strong CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine) may increase aripiprazole concentrations. Strong CYP3A4 inducers (carbamazepine, rifampin) may decrease concentrations. Caution is advised when combining with other central nervous system depressants including alcohol, benzodiazepines, and opioids. Antihypertensive medications may potentiate orthostatic hypotension. Serotonergic drugs may increase risk of serotonin syndrome. Lithium and other mood stabilizers may require monitoring when combined with Abilify.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. For the long-acting injectable formulation, healthcare providers should be contacted immediately if an injection is missed to determine the appropriate course of action, as the dosing schedule may need to be adjusted.
Overdose
In case of overdose, supportive medical care should be initiated immediately. Symptoms may include sedation, vomiting, agitation, aggression, confusion, tremors, seizures, coma, and potentially fatal outcomes in severe cases. Medical monitoring should include cardiac function and vital signs. There is no specific antidote for aripiprazole overdose; treatment is symptomatic and supportive. Activated charcoal may be considered if ingestion was recent. Dialysis is unlikely to be beneficial due to high protein binding and extensive tissue distribution.
Storage
Tablets and orally disintegrating tablets should be stored at room temperature (15-30°C or 59-86°F) in their original container, protected from light and moisture. The oral solution should be stored at room temperature and used within 6 months of opening; do not freeze. Unused portions should be discarded appropriately. All medications should be kept out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Proper disposal methods should be followed for unused medication, preferably through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Abilify is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to medication varies, and only a healthcare provider can determine the appropriate treatment based on a patient’s specific medical condition, history, and current medications. Patients should not initiate, discontinue, or change dosage without medical consultation. The complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies demonstrate that Abilify shows significant efficacy in reducing symptoms of schizophrenia, with response rates typically between 40-60% in controlled trials. In bipolar disorder, it has shown robust antimanic effects and maintenance benefits. As adjunctive treatment for depression, multiple studies have demonstrated statistically significant improvement in depressive symptoms compared to antidepressant monotherapy. Patient-reported outcomes often note improved functionality and quality of life, though individual experiences with side effects vary. Long-term studies support maintained efficacy with continuous treatment. Real-world evidence generally aligns with clinical trial data, though effectiveness in routine practice may be influenced by numerous factors including adherence, comorbidities, and psychosocial support.